|
| Product/agent | Nanoplatform | Indication | Status | Company |
|
| Cyclosert | Cyclodextrin nanoparticles (Cyclodextrin NP/SiRNA) | Solid tumors | Phase I | Insert Therapeutics
(now Calando Pharmaceuticals) |
| CRLX101 | Cyclodextrin NPs/Camptothecin | Various cancers | Phase II | Cerulean Pharma |
| S-CKD602 | PEGylated liposomal CKD602 (topoisomerase inhibitor) | Various cancers | Phase I/II | Alza Corporation |
| CPX-1 | Liposomal irinotecan | Colorectal cancer | Phase II | Celator Pharmaceuticals |
| CPX-351 | Liposomal cytarabine and daunorubicin | Acute myeloid leukemia | Phase I | Celator Pharmaceuticals |
| LE-SN38 | Liposomal SN38 | Colorectal cancer | Phase II | Neopharm |
| INGN-401 | Liposomal/FUS1 | Lung cancer | Phase I | Introgen |
| NC-6004 | Polymeric nanoparticle (PEG-polyaspartate) formulation of cisplatin | Various cancers | Phase I | NanoCarrier Co. |
| NK-105 | Polymeric nanoparticle (PEG-polyaspartate) formulation of paclitaxel | Various cancers | Phase II | Nippon Kayaku Co. Ltd. |
| NK-911 | Polymeric nanoparticle (PEG-polyaspartate) formulation of doxorubicin | Various cancers | Phase I | Nippon Kayaku Co. Ltd. |
| NK-012 | Polymeric micelle of SN-38 | Various cancers | Phase II | Nippon Kayaku Co. Ltd. |
| SP1049C | Glycoprotein of doxorubicin | Various cancers | Phase II | Supratek Pharma Inc. |
| SPI-077 | PEGylated liposomal cisplatin | Head/neck and lung cancer | Phase II | Alza Corporation |
| ALN-VSP | Lipid nanoparticle formulation of siRNA | Liver cancer | Phase I | Alnylam Pharmaceuticals |
| OSI-7904L | Liposomal thymidylate synthase inhibitor | Various cancers | Phase II | OSI Pharmaceuticals |
| OSI-211 | Liposomal lurtotecan | Various cancers | Phase II | OSI Pharmaceuticals |
| Combidex | Iron oxide | Tumor imaging | Phase III | Advanced Magnetics |
| Aurimune | Colloidal gold/TNF | Solid tumors | Phase II | CytImmune Sciences |
| SGT-53 | Liposome Tf antibody/p53 gene | Solid tumors | Phase I | SynerGene Therapeutics |
| BIND-014 | PLGA/PLA NPs/Docetaxel | Prostate cancer and others | Phase I | BIND Biosciences |
| AuroLase | Gold-coated silica NPs | Head and neck cancer | Phase I | Nanospectra Biosciences |
| Rexin-G | Targeting protein tagged phospholipid/microRNA-122 | Sarcoma, osteosarcoma, pancreatic cancer, and other solid tumor | Phase II/III (Fast Track Designation, Orphan Drug Status Acquired) in USA fully approved in Philippine | Epeius Biotechnologies Corp. |
| ThermoDox | Heat-activated liposomal encapsulation of doxorubicin | Breast cancer, primary liver cancer | Approved for Breast Cancer; Phase III for primary liver cancer | Celsion |
| BIND-014 | Polymeric nanoparticle formulation of docetaxel | Various cancers | Phase I | BIND Bioscience |
| SGT53-01 | Transferrin targeted liposome with p53 gene | Solid tumors | Phase I | SynerGene Therapeutics |
| PEG-PGA and DON | PEG-glutaminase combined with glutamine antimetabolite 6-diazo-5-oxo-l-norleucine (DON) | Various cancers | Phase I/II | EvaluatePharma |
| PEG-IFNα2a | PEG-asys | Melanoma, chromic myeloid leukemia, and renal-cell carcinoma | Phase I/II | Genentech |
| PEG-IFNα2b | PEG-Intron | Melanoma, multiple myeloid, and renal-cell carcinoma | Phase I/II | Merck |
| ADI-PEG20 | PEG-arginine deiminase | Hepatocellular carcinoma | Phase I | Polaris |
|
